No Data
No Data
RBC Capital Maintains Applied Therapeutics(APLT.US) With Hold Rating, Cuts Target Price to $1.5
Applied Therapeutics Is Maintained at Sector Perform by RBC Capital
Applied Therapeutics Price Target Cut to $1.50/Share From $4.00 by RBC Capital
Applied Therapeutics Analyst Ratings
Applied Therapeutics CEO Shendelman Steps Down
Applied Therapeutics Faces Leadership Changes and Regulatory Hurdles
No Data